Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.62 |
| ▸ | NPY1R | P25929 | 3/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | FURIN | P09958 | 6/20 | 0.49 |
| ▸ | NPY4R | P50391 | 1/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14117893 | 0.94 | CHRM2 (0.69) | SIRT5CHRM2CHRM4CHRM1NPY1R | |
| Trifluoroacetic Acid SCHEMBL31741398 | 0.91 | SIRT5 (0.59) | SIRT5CHRM2CHRM4CHRM1NPY1R | |
| SCHEMBL30080701 | 0.90 | CHRM2 (0.58) | SIRT5CHRM2CHRM4CHRM1NPY1R | |
| SCHEMBL31154645 | 0.87 | SIRT5 (0.59) | SIRT5CHRM2CHRM4CHRM1FURIN | |
| SCHEMBL29398996 | 0.86 | CYP1A2 (0.54) | SIRT5CHRM2CHRM4CHRM1NPY1R | |
| SCHEMBL29595648 | 0.86 | FURIN (0.56) | SIRT5CHRM2CHRM4CHRM1NPY1R | |
| SCHEMBL13337947 | 0.86 | CHRM2 (0.64) | SIRT5CHRM2CHRM4CHRM1NPY1R | |
| SCHEMBL29546257 | 0.86 | CHRM2 (0.64) | SIRT5CHRM2CHRM4CHRM1NPY1R | |
| SCHEMBL16748402 | 0.82 | CHRM2 (0.68) | SIRT5CHRM2CHRM4CHRM1CA1 | |
| SCHEMBL29521677 | 0.82 | CHRM2 (0.68) | SIRT5CHRM2CHRM4CHRM1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724096-A1 | GPCR INHIBITORS AND USES THEREOF | GPCR Therapeutics, Inc. (KR) | 2026-04-15 | — | — | EP | claimed |
| US-20250381168-A1 | VLA4 INHIBITORS AND USES THEREOF | WASHINGTON UNIVERSITY ST LOUIS (US) | 2025-12-18 | — | — | US | claimed |
| EP-4660299-A1 | PRODUCTION OF BLOOD AND IMMUNE CELL PROGENITORS | PHILIPPS-UNIVERSITÄT MARBURG (DE) | 2025-12-10 | — | — | EP | claimed |
| US-20250360149-A1 | GPCR INHIBITORS AND USES THEREOF | GPCR THERAPEUTICS INC (KR) | 2025-11-27 | — | — | US | claimed |
| EP-4577662-A1 | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF RECOMBINANT ADENO-ASSOCIATED VIRUS (RAAV) VECTORS | Beacon Therapeutics (USA), Inc. (US) | 2025-07-02 | — | — | EP | claimed |
| EP-4536239-A1 | GPCR INHIBITORS AND USES THEREOF | GPCR Therapeutics, Inc. (KR) | 2025-04-16 | — | — | EP | claimed |
| CN-222721481-U | Signal conversion circuit | 陕西嵌图电子科技有限公司 | 2025-04-04 | — | — | CN | claimed |
| WO-2025050038-A2 | GPCR INHIBITORS AND USES THEREOF | GPCR THERAPEUTICS, INC. (KR) | 2025-03-06 | — | — | WO | claimed |
| CN-119562815-A | GPCR inhibitors and uses thereof | GPCR治疗公司 | 2025-03-04 | — | — | CN | claimed |
| CN-119094265-A | System and method for realizing multi-channel CAN data receiving and transmitting by DSP | 陕西嵌图电子科技有限公司 | 2024-12-06 | — | — | CN | claimed |
| CN-118767162-A | Immobilized enzyme nanogel and preparation method and application thereof | 山东大学 | 2024-10-15 | — | — | CN | claimed |
| WO-2024157207-A1 | GPCR INHIBITORS AND USES THEREOF | GPCR THERAPEUTICS, INC. (KR) | 2024-08-02 | — | — | WO | claimed |
| EP-4380602-A2 | ADENO-ASSOCIATED VIRAL (AAV)-MEDIATED SPHINGOSINE-1-PHOSPHATE LYASE (SPL) EXPRESSION FOR TREATING PULMONARY FIBROSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-12 | — | — | EP | claimed |
| WO-2024044340-A1 | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF RECOMBINANT ADENO-ASSOCIATED VIRUS (RAAV) VECTORS | BEACON THERAPEUTICS (USA), INC. (US) | 2024-02-29 | — | — | WO | claimed |
| CN-117343930-A | Application of long-chain non-coding RNA in preparation of medicines for treating cardiac hypertrophy and/or heart failure | 中山大学附属第一医院 | 2024-01-05 | — | — | CN | claimed |
| US-11857600-B2 | GPCR heteromer inhibitors and uses thereof | GPCR THERAPEUTICS, INC. (KR) | 2024-01-02 | — | — | US | claimed |
| WO-2023250339-A2 | VLA4 INHIBITORS AND USES THEREOF | WASHINGTON UNIVERSITY (US) | 2023-12-28 | — | — | WO | claimed |
| WO-2023239937-A1 | GPCR INHIBITORS AND USES THEREOF | GPCR THERAPEUTICS, INC. (KR) | 2023-12-14 | — | — | WO | claimed |
| CN-116271100-A | Nanometer gel based on immobilized collagenase and preparation method and application thereof | 山东大学 | 2023-06-23 | — | — | CN | claimed |
| WO-2023015189-A2 | ADENO-ASSOCIATED VIRAL (AAV)-MEDIATED SPHINGOSINE-1-PHOSPHATE LYASE (SPL) EXPRESSION FOR TREATING PULMONARY FIBROSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381168-A1 | VLA4 INHIBITORS AND USES THEREOF | CXCR4, SDF4, ITGB4 | SIRT5 4372/4885CHRM2 2292/4885CHRM4 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.